336 related articles for article (PubMed ID: 33925671)
1. Prognostic Role of Plasma PD-1, PD-L1, pan-BTN3As and BTN3A1 in Patients Affected by Metastatic Gastrointestinal Stromal Tumors: Can Immune Checkpoints Act as a Sentinel for Short-Term Survival?
Fanale D; Incorvaia L; Badalamenti G; De Luca I; Algeri L; Bonasera A; Corsini LR; Brando C; Russo A; Iovanna JL; Bazan V
Cancers (Basel); 2021 Apr; 13(9):. PubMed ID: 33925671
[TBL] [Abstract][Full Text] [Related]
2. Can circulating PD-1, PD-L1, BTN3A1, pan-BTN3As, BTN2A1 and BTLA levels enhance prognostic power of CA125 in patients with advanced high-grade serous ovarian cancer?
Fanale D; Corsini LR; Brando C; Cutaia S; Di Donna MC; Filorizzo C; Lisanti MC; Randazzo U; Magrin L; Romano R; Bazan Russo TD; Olive D; Vieni S; Pantuso G; Chiantera V; Russo A; Bazan V; Iovanna JL
Front Oncol; 2022; 12():946319. PubMed ID: 36212445
[TBL] [Abstract][Full Text] [Related]
3. Low plasma PD-L1 levels, early tumor onset and absence of peritoneal carcinomatosis improve prognosis of women with advanced high-grade serous ovarian cancer.
Fanale D; Brando C; Corsini LR; Cutaia S; Di Donna MC; Randazzo U; Filorizzo C; Lisanti C; Magrin L; Gurrera V; Romano R; Dimino A; Bazan Russo TD; Olive D; Vieni S; Pantuso G; Giordano A; Chiantera V; Russo A; Bazan V; Iovanna JL
BMC Cancer; 2023 May; 23(1):437. PubMed ID: 37179293
[TBL] [Abstract][Full Text] [Related]
4. Baseline plasma levels of soluble PD-1, PD-L1, and BTN3A1 predict response to nivolumab treatment in patients with metastatic renal cell carcinoma: a step toward a biomarker for therapeutic decisions.
Incorvaia L; Fanale D; Badalamenti G; Porta C; Olive D; De Luca I; Brando C; Rizzo M; Messina C; Rediti M; Russo A; Bazan V; Iovanna JL
Oncoimmunology; 2020 Oct; 9(1):1832348. PubMed ID: 33178494
[TBL] [Abstract][Full Text] [Related]
5. Prognostic significance of circulating PD-1, PD-L1, pan-BTN3As, BTN3A1 and BTLA in patients with pancreatic adenocarcinoma.
Bian B; Fanale D; Dusetti N; Roque J; Pastor S; Chretien AS; Incorvaia L; Russo A; Olive D; Iovanna J
Oncoimmunology; 2019; 8(4):e1561120. PubMed ID: 30906655
[TBL] [Abstract][Full Text] [Related]
6. Prognostic role of soluble PD-1 and BTN2A1 in overweight melanoma patients treated with nivolumab or pembrolizumab: finding the missing links in the symbiotic immune-metabolic interplay.
Incorvaia L; Rinaldi G; Badalamenti G; Cucinella A; Brando C; Madonia G; Fiorino A; Pipitone A; Perez A; Li Pomi F; Galvano A; Gristina V; Barraco N; Bono M; Bazan Russo TD; Toia F; Cordova A; Fanale D; Russo A; Bazan V
Ther Adv Med Oncol; 2023; 15():17588359231151845. PubMed ID: 36818688
[TBL] [Abstract][Full Text] [Related]
7. Dynamic monitoring of serum soluble programmed cell death ligand 1 as a response predictor to chemotherapy in metastatic or recurrent gastrointestinal cancer.
Sun J; Qiu MZ; Mei T; Gao Y; Chang B; Zhang Y; Wang FH; Li S
Transl Cancer Res; 2020 Apr; 9(4):2434-2448. PubMed ID: 35117603
[TBL] [Abstract][Full Text] [Related]
8. Type and Gene Location of
Incorvaia L; Fanale D; Vincenzi B; De Luca I; Bartolotta TV; Cannella R; Pantuso G; Cabibi D; Russo A; Bazan V; Badalamenti G
Cancers (Basel); 2021 Feb; 13(5):. PubMed ID: 33673554
[TBL] [Abstract][Full Text] [Related]
9. PD-1/PD-L1 Blockade Enhances T-cell Activity and Antitumor Efficacy of Imatinib in Gastrointestinal Stromal Tumors.
Seifert AM; Zeng S; Zhang JQ; Kim TS; Cohen NA; Beckman MJ; Medina BD; Maltbaek JH; Loo JK; Crawley MH; Rossi F; Besmer P; Antonescu CR; DeMatteo RP
Clin Cancer Res; 2017 Jan; 23(2):454-465. PubMed ID: 27470968
[TBL] [Abstract][Full Text] [Related]
10. Soluble PD-L1 Is an Independent Prognostic Factor in Clear Cell Renal Cell Carcinoma.
Larrinaga G; Solano-Iturri JD; Errarte P; Unda M; Loizaga-Iriarte A; Pérez-Fernández A; Echevarría E; Asumendi A; Manini C; Angulo JC; López JI
Cancers (Basel); 2021 Feb; 13(4):. PubMed ID: 33562338
[TBL] [Abstract][Full Text] [Related]
11. Characterization of soluble PD-L1 in pleural effusions of mesothelioma patients: potential implications in the immune response and prognosis.
Carosio R; Fontana V; Mastracci L; Ferro P; Grillo F; Banelli B; Canessa PA; Dessanti P; Vigani A; Morabito A; Pfeffer U; Poggi A; Roncella S; Pistillo MP
J Cancer Res Clin Oncol; 2021 Feb; 147(2):459-468. PubMed ID: 33216211
[TBL] [Abstract][Full Text] [Related]
12. Serum levels of soluble programmed death ligand 1 predict treatment response and progression free survival in multiple myeloma.
Wang L; Wang H; Chen H; Wang WD; Chen XQ; Geng QR; Xia ZJ; Lu Y
Oncotarget; 2015 Dec; 6(38):41228-36. PubMed ID: 26515600
[TBL] [Abstract][Full Text] [Related]
13. The Prognostic Value of Plasma Programmed Death Protein-1 (PD-1) and Programmed Death-Ligand 1 (PD-L1) in Patients with Gastrointestinal Stromal Tumor.
Brinch CM; Hogdall E; Junker N; Moeller HJ; Sandfeld-Paulsen B; de Heer P; Penninga L; Rossen PB; Krarup-Hansen A; Aggerholm-Pedersen N
Cancers (Basel); 2022 Nov; 14(23):. PubMed ID: 36497235
[TBL] [Abstract][Full Text] [Related]
14. Predictive Value of Soluble PD-1, PD-L1, VEGFA, CD40 Ligand and CD44 for Nivolumab Therapy in Advanced Non-Small Cell Lung Cancer: A Case-Control Study.
Tiako Meyo M; Jouinot A; Giroux-Leprieur E; Fabre E; Wislez M; Alifano M; Leroy K; Boudou-Rouquette P; Tlemsani C; Khoudour N; Arrondeau J; Thomas-Schoemann A; Blons H; Mansuet-Lupo A; Damotte D; Vidal M; Goldwasser F; Alexandre J; Blanchet B
Cancers (Basel); 2020 Feb; 12(2):. PubMed ID: 32085544
[TBL] [Abstract][Full Text] [Related]
15. Plasma soluble programmed death ligand 1 levels predict clinical response in peripheral T-cell lymphomas.
Zhang X; Liu L; Zhou S; Zhao K; Song Z; Hu G; Zhang T; Li Y; Qiu L; Li L; Qian Z; Meng B; Pan Y; Ren X; Wang X; Zhang H; Fu K
Hematol Oncol; 2019 Aug; 37(3):270-276. PubMed ID: 31074879
[TBL] [Abstract][Full Text] [Related]
16. High Serum Level of Soluble Programmed Death Ligand 1 is Associated With a Poor Prognosis in Hodgkin Lymphoma.
Guo X; Wang J; Jin J; Chen H; Zhen Z; Jiang W; Lin T; Huang H; Xia Z; Sun X
Transl Oncol; 2018 Jun; 11(3):779-785. PubMed ID: 29698935
[TBL] [Abstract][Full Text] [Related]
17. High plasma levels of soluble programmed cell death ligand 1 are prognostic for reduced survival in advanced lung cancer.
Okuma Y; Hosomi Y; Nakahara Y; Watanabe K; Sagawa Y; Homma S
Lung Cancer; 2017 Feb; 104():1-6. PubMed ID: 28212990
[TBL] [Abstract][Full Text] [Related]
18. High post-treatment serum levels of soluble programmed cell death ligand 1 predict early relapse and poor prognosis in extranodal NK/T cell lymphoma patients.
Wang H; Wang L; Liu WJ; Xia ZJ; Huang HQ; Jiang WQ; Li ZM; Lu Y
Oncotarget; 2016 May; 7(22):33035-45. PubMed ID: 27105512
[TBL] [Abstract][Full Text] [Related]
19. Serum levels of soluble programmed cell death ligand 1 as a prognostic factor on the first-line treatment of metastatic or recurrent gastric cancer.
Takahashi N; Iwasa S; Sasaki Y; Shoji H; Honma Y; Takashima A; Okita NT; Kato K; Hamaguchi T; Yamada Y
J Cancer Res Clin Oncol; 2016 Aug; 142(8):1727-38. PubMed ID: 27256004
[TBL] [Abstract][Full Text] [Related]
20. Serum levels of soluble programmed death-ligand 1 (sPD-L1) in patients with primary central nervous system diffuse large B-cell lymphoma.
Cho I; Lee H; Yoon SE; Ryu KJ; Ko YH; Kim WS; Kim SJ
BMC Cancer; 2020 Feb; 20(1):120. PubMed ID: 32054467
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]